Findings of Research Misconduct, 26065-26066 [2018-12047]
Download as PDF
26065
Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices
Number of
respondents
Form name
Number of
responses per
respondent
Total
responses
Average burden per
response
(in hours)
Total burden
hours
INITIAL Survey of the Secretary’s Discretionary Advisory
Committee on Heritable Disorders in Newborns and
Children’s Public Health System Assessment 1 ...............
FOLLOW–UP Survey of the Secretary’s Discretionary Advisory Committee on Heritable Disorders in Newborns
and Children’s Public Health System Assessment ..........
59
1
59
10
590
2 30
1
30
2
60
Total ..............................................................................
89
........................
89
........................
650
1 The
respondents to the survey will be State and territorial newborn screening programs.
2 Up to 30 States and/or Territories will be asked to complete a follow-up survey.
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2018–12019 Filed 6–4–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Tick-Borne Disease
Working Group
Office of the Secretary, Office
of the Assistant Secretary for Health,
Office of HIV/AIDS and Infectious
Disease Policy, Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) announces the
sixth meeting of the Tick-Borne Disease
Working Group (Working Group) on
June 21, 2018, from 9:30 a.m. to 6:00
p.m., Eastern Time. The sixth meeting
will be an on-line meeting held via
webcast. The Working Group will focus
on subcommittee findings and will
review and provide input on the content
of the five chapters that will be
submitted into the Working Group
Congressional Report.
DATES: The on-line meeting will be held
on June 21, 2018, from 9:30 a.m. to 6:00
p.m. Eastern Time.
ADDRESSES: This will be an on-line
meeting that is held via webcast.
Members of the public may attend the
meeting via webcast. Instructions for
attending this virtual meeting will be
amozie on DSK3GDR082PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
20:19 Jun 04, 2018
Jkt 241001
posted prior to the meeting at: https://
www.hhs.gov/ash/advisory-committees/
tickbornedisease/.
FOR FURTHER INFORMATION CONTACT:
James Berger, Office of HIV/AIDS and
Infectious Disease Policy, Office of the
Assistant Secretary for Health,
Department of Health and Human
Services; via email at tickbornedisease@
hhs.gov or by phone at 202–795–7697.
SUPPLEMENTARY INFORMATION: The
Working Group invites public comment
on issues related to the Working Group’s
charge. Comments may be provided
over the phone during the meeting or in
writing. Persons who wish to provide
comments by phone should review
directions at https://www.hhs.gov/ash/
advisory-committees/tickbornedisease/
meetings/ before submitting a
request via email at tickbornedisease@
hhs.gov on or before June 18, 2018.
Phone comments will be limited to
three minutes each to accommodate as
many speakers as possible. A total of 30
minutes will be allocated to public
comments. If more requests are received
than can be accommodated, speakers
will be randomly selected. The nature of
the comments will not be considered in
making this selection. Public comments
may also be provided in writing.
Individuals who would like to provide
written comment should review
directions at https://www.hhs.gov/ash/
advisory-committees/tickbornedisease/
meetings/ before sending
their comments to tickbornedisease@
hhs.gov on or before June 18, 2018.
During the meeting, the Working
Group will review and discuss the
content of the five draft chapters that
will be part of the Report to Congress.
Persons who wish to receive the draft
document should email the
tickbornedisease@hhs.gov and request a
copy. The document will be available
prior to the meeting.
Background and Authority: The TickBorne Disease Working Group was
established on August 10, 2017, in
accordance with section 2062 of the 21st
Century Cures Act, and the Federal
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Advisory Committee Act, 5 U.S.C. App.,
as amended, to provide expertise and
review all HHS, DoD and VA efforts
related to tick-borne diseases to help
ensure interagency coordination and
minimize overlap, examine research
priorities, and identify and address
unmet needs. In addition, the Working
Group is required to submit a report to
the Secretary and Congress on their
findings and any recommendations for
improving the federal response to tickborne disease prevention, treatment and
research, and addressing gaps in those
areas.
Dated: May 31, 2018.
James Berger,
Office of HIV/AIDS and Infectious Disease
Policy, Designated Federal Officer, TickBorne Disease Working Group.
[FR Doc. 2018–12045 Filed 6–4–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made on the part
of Shiladitya Sen, former graduate
student, Department of Chemistry and
Biochemistry, The Ohio State University
(OSU). Mr. Sen engaged in research
misconduct in research supported by
National Institute of General Medical
Sciences (NIGMS), National Institutes of
Health (NIH), grant R01 GM083114. The
administrative actions, including
debarment for a period of three (3)
years, were implemented beginning on
May 16, 2018, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUMMARY:
E:\FR\FM\05JNN1.SGM
05JNN1
26066
Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices
Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Shiladitya Sen, The Ohio State
University: Based on the report of an
investigation conducted by OSU and
analysis conducted by ORI in its
oversight review, ORI found that Mr.
Shiladitya Sen, former graduate student,
OSU, engaged in research misconduct in
research supported by NIGMS, NIH,
grant R01 GM083114.
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally falsifying and/or
fabricating data reported in the
following published paper, his Ph.D.
thesis, a poster presentation, and his
mentor’s grant applications submitted to
NIGMS, NIH:
• PNAS 110(11):4261–4266, 2013
(hereafter referred to as ‘‘PNAS
2013’’); retracted in: PNAS
114(37):E7855, 2017 Sep
• Sen, S. ‘‘Engineering Proteins for
Enhanced Stability using HighThroughput and Combinatorial
Methods.’’ OSU Doctoral Dissertation,
2013 (hereafter referred to as ‘‘thesis’’)
• poster presented at the Annual
Symposium of the Protein Society in
2012 (hereafter referred to as ‘‘Poster
2012’’)
• R01 GM083114 and R01 GM083114–
A1
ORI found that Respondent
knowingly and intentionally falsified
and/or fabricated gene sequencing and
high throughput thermal scanning
(HTTS) data for sequence-stability
relationship of Rop protein variants in
nineteen (19) figures, ten (10) tables,
and related text included in a poster
presentation, his Ph.D. thesis, and two
(2) NIH grant applications.
Specifically, Respondent knowingly
and intentionally falsified and/or
fabricated:
• Unique sequences and stability data
for 1017 active Rop variants in Table
3.1 and provided additional analyses
purportedly from those active Rop
variants in Table 3.2 and Figures 3.3,
3.4, 3.5, 3.6, 3.7, 3.8, and 3.9 in his
thesis and in Figures 6, 7, 17, and 20
in two (2) grant applications
• unique sequences and stability data
for active Rop loop variants from four
separate mutant libraries, X4, LX4, X4I, LX4-I in Tables 5.2, 5.3, 5.4, and 5.5,
respectively, and presented additional
analyses purportedly from those
active Rop loop variants in Figures
5.3, 5.4, 5.5, 5.6, and 5.9 and Table 5.1
in his thesis and in Figure 6 in two
(2) grant applications
• figures entitled ‘‘analysis of more than
1000 active (folded) core variants,’’
amozie on DSK3GDR082PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
20:19 Jun 04, 2018
Jkt 241001
‘‘Loop Library: How does loop affect
stability?’’ and ‘‘Detailed
characterization of loop variants’’ in
Poster 2012
• list of oligonucleotides included in
Tables 9.2, 9.3, and 9.4 in his thesis
ORI also found that Respondent
knowingly and intentionally falsified
and/or fabricated HTTS data for
thermodynamic effects of somatic
mutation in antibodies 93F3 and OKT3
in ten (10) figures, two (2) tables, and
related text included in PNAS 2013 and
his thesis.
Specifically, Respondent knowingly
and intentionally falsified and/or
fabricated HTTS data:
• In Figures 6.2A, 6.2C, 6.3, and 6.6 and
Tables 6.2 and 6.3 in his thesis
• also included as Figures 2A, 2C, S2,
and S5 and Tables S3 and S4 in PNAS
2013
Mr. Sen entered into a Voluntary
Exclusion Agreement and voluntarily
agreed for a period of three (3) years,
beginning on May 16, 2018:
(1) To exclude himself voluntarily
from any contracting or subcontracting
with any agency of the United States
Government and from eligibility for or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ pursuant to HHS’
Implementation (2 CFR part 376) of
OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’);
(2) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–12047 Filed 6–4–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Psychosocial Risk and Disease Prevention.
Date: June 12, 2018.
Time: 8:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Mayflower Park Hotel, 405 Olive
Way, Seattle, WA 98101.
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, (301) 594–
3292, niw@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Risk
Prevention and Health Behavior AREA
Review.
Date: June 19, 2018.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: John H Newman, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3222,
MSC 7808, Bethesda, MD 20892, (301) 435–
0628, newmanjh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Atherosclerosis, Inflammation, Molecular
and Cellular Hematology.
Date: June 25, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Katherine M Malinda,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4140,
MSC 7814, Bethesda, MD 20892, 301–435–
0912, Katherine_Malinda@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Integrative Neuroscience.
Date: June 25, 2018.
Time: 12:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ying-Yee Kong, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5185,
Bethesda, MD 20892, ying-yee.kong@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
E:\FR\FM\05JNN1.SGM
05JNN1
Agencies
[Federal Register Volume 83, Number 108 (Tuesday, June 5, 2018)]
[Notices]
[Pages 26065-26066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12047]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made on the part of
Shiladitya Sen, former graduate student, Department of Chemistry and
Biochemistry, The Ohio State University (OSU). Mr. Sen engaged in
research misconduct in research supported by National Institute of
General Medical Sciences (NIGMS), National Institutes of Health (NIH),
grant R01 GM083114. The administrative actions, including debarment for
a period of three (3) years, were implemented beginning on May 16,
2018, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8200.
[[Page 26066]]
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Shiladitya Sen, The Ohio State University: Based on the report of
an investigation conducted by OSU and analysis conducted by ORI in its
oversight review, ORI found that Mr. Shiladitya Sen, former graduate
student, OSU, engaged in research misconduct in research supported by
NIGMS, NIH, grant R01 GM083114.
ORI found that Respondent engaged in research misconduct by
knowingly and intentionally falsifying and/or fabricating data reported
in the following published paper, his Ph.D. thesis, a poster
presentation, and his mentor's grant applications submitted to NIGMS,
NIH:
PNAS 110(11):4261-4266, 2013 (hereafter referred to as ``PNAS
2013''); retracted in: PNAS 114(37):E7855, 2017 Sep
Sen, S. ``Engineering Proteins for Enhanced Stability using
High-Throughput and Combinatorial Methods.'' OSU Doctoral Dissertation,
2013 (hereafter referred to as ``thesis'')
poster presented at the Annual Symposium of the Protein
Society in 2012 (hereafter referred to as ``Poster 2012'')
R01 GM083114 and R01 GM083114-A1
ORI found that Respondent knowingly and intentionally falsified
and/or fabricated gene sequencing and high throughput thermal scanning
(HTTS) data for sequence-stability relationship of Rop protein variants
in nineteen (19) figures, ten (10) tables, and related text included in
a poster presentation, his Ph.D. thesis, and two (2) NIH grant
applications.
Specifically, Respondent knowingly and intentionally falsified and/
or fabricated:
Unique sequences and stability data for 1017 active Rop
variants in Table 3.1 and provided additional analyses purportedly from
those active Rop variants in Table 3.2 and Figures 3.3, 3.4, 3.5, 3.6,
3.7, 3.8, and 3.9 in his thesis and in Figures 6, 7, 17, and 20 in two
(2) grant applications
unique sequences and stability data for active Rop loop
variants from four separate mutant libraries, X4,
LX4, X4-I, LX4-I in Tables 5.2, 5.3,
5.4, and 5.5, respectively, and presented additional analyses
purportedly from those active Rop loop variants in Figures 5.3, 5.4,
5.5, 5.6, and 5.9 and Table 5.1 in his thesis and in Figure 6 in two
(2) grant applications
figures entitled ``analysis of more than 1000 active (folded)
core variants,'' ``Loop Library: How does loop affect stability?'' and
``Detailed characterization of loop variants'' in Poster 2012
list of oligonucleotides included in Tables 9.2, 9.3, and 9.4
in his thesis
ORI also found that Respondent knowingly and intentionally
falsified and/or fabricated HTTS data for thermodynamic effects of
somatic mutation in antibodies 93F3 and OKT3 in ten (10) figures, two
(2) tables, and related text included in PNAS 2013 and his thesis.
Specifically, Respondent knowingly and intentionally falsified and/
or fabricated HTTS data:
In Figures 6.2A, 6.2C, 6.3, and 6.6 and Tables 6.2 and 6.3 in
his thesis
also included as Figures 2A, 2C, S2, and S5 and Tables S3 and
S4 in PNAS 2013
Mr. Sen entered into a Voluntary Exclusion Agreement and
voluntarily agreed for a period of three (3) years, beginning on May
16, 2018:
(1) To exclude himself voluntarily from any contracting or
subcontracting with any agency of the United States Government and from
eligibility for or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' pursuant to
HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively
the ``Debarment Regulations'');
(2) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-12047 Filed 6-4-18; 8:45 am]
BILLING CODE 4150-31-P